GlassScriptPhysician profile
Michael A Rocklin
NPI 1063494367
$1,823.34
in general payments reported to CMS, 2019-2025
18 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $121 · 2021: $188 · 2022: $228 · 2023: $566 · 2024: $458 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,133 · Education: $33.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,133.48 |
| Education | $33.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $268.68 | 2020-2024 | Tavneos, Krystexxa, Aranesp |
| Glaxosmithkline, LLC. | $233.86 | 2020-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $202.57 | 2021-2023 | Farxiga |
| Horizon Therapeutics Plc | $164.51 | 2022-2023 | Krystexxa |
| Vifor Pharma, INC. | $161.25 | 2019-2024 | Veltassa |
| Akebia Therapeutics INC | $125.00 | 2024 | Vafseo, Auryxia |
| Bayer Healthcare Pharmaceuticals INC. | $114.93 | 2022-2024 | |
| Travere Therapeutics, INC. | $99.98 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $88.81 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $83.02 | 2023-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $74.97 | 2022-2023 | Jynarque |
| Aurinia Pharma U.S., INC. | $49.83 | 2022-2023 | Lupkynis |
| Cycle Pharmaceuticals INC | $32.80 | 2025 | Venxxiva |
| Novo Nordisk INC | $30.10 | 2024 | Rivfloza |
| Alexion Pharmaceuticals, INC. | $27.53 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $25.46 | 2019 | |
| Baxter Healthcare | $24.51 | 2023 | Renal - Acute |
| Scpharmaceuticals INC. | $15.53 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rocklin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.